Concepedia

Sharadha Subramanian

SS

Statistics

Publications

16

Citations

556

H-Index

13

Active since

2006

Affiliations

Novartis (Switzerland)(Current)

Novartis (United States)

Genomics Institute of the Novartis Research Foundation

Gilead Sciences (United States)

Sharadha Subramanian is an author at Novartis (Switzerland) specializing in drug discovery, medicinal chemistry, and drug design.

Publications per year

2006–2020

16

Publications

16

Discovery of Potent and Selective RSK Inhibitors as Biological Probes

Rama Jain, Michelle Mathur, Jiong Lan et al. · Journal of Medicinal Chemistry · 2015 · 83 citations · Full text

, , +13

Design and Synthesis of Orally Bioavailable Benzimidazoles as Raf Kinase Inhibitors

Savithri Ramurthy, Sharadha Subramanian, Mina Aikawa et al. · Journal of Medicinal Chemistry · 2008 · 76 citations · Full text

, , +13

Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma

Teresa E. Williams, Sharadha Subramanian, Joelle Verhagen et al. · ACS Medicinal Chemistry Letters · 2015 · 54 citations · Full text

, , +17

Design and Discovery of <i>N</i>-(2-Methyl-5′-morpholino-6′-((tetrahydro-2<i>H</i>-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers

Gisele Nishiguchi, Alice Rico, Huw R. Tanner et al. · Journal of Medicinal Chemistry · 2017 · 44 citations · Full text

, , +15

Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic

Savithri Ramurthy, Benjamin R. Taft, Robert J. Aversa et al. · Journal of Medicinal Chemistry · 2019 · 40 citations · Full text

, , +17

1–5 of 16